Technologies

Our researchers have discovered that two key proteins, the dopamine D2 receptor (D2R) and the protein “disrupted in schizophrenia 1” (DISC1), form a protein‐protein interaction complex which has been shown to contribute to the pathophysiology of schizophrenia. Through the characterization of the protein‐protein interaction, we have developed a peptide that specifically interferes with this coupling; leading to the development of a breakthrough therapy capable of delivering enhanced affinity, efficacy, and a superior side effect profile.